Two additional changes in VRTX’s guidance from today’s PR:
4. Evidently, there is no longer any plan to disclose the top-line results of the VX-222 phase-1b monotherapy study prior to presentation of the full dataset at an unspecified medical conference in 2010. Previously, VRTX had promised to report the top-line data in 4Q09.
5. There is no plan to report the results of a Telaprvir/VX-222 drug-drug-interaction study. Previously, VRTX had said that these data might be reported to investors.
Market Data 
Markets 
AI
